CompletedPhase 4

LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

729 participantsStarted 2005-04

Plain-language summary

Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * At least 2-year history of Allergic Rhinitis that became symptomatic during the annual grass pollen season. * A skin test for grass pollens positive: * Have rhinitis symptoms of such severity that the mean T4SS over the baseline period must be 6. Exclusion Criteria: * Have an associated asthma requiring corticosteroid treatment, * Have an atopic dermatitis or an urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids,

What they're measuring

Mean change from baseline of T4SS (four symptoms score) over two weeks of treatment

Trial details

NCT IDNCT00160589

SponsorUCB Pharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-09

View on ClinicalTrials.gov More Rhinitis, Allergic, Perennial trials